According to A Latest intelligence report published by Market IntelliX, the global market for Pharmaceutical CDMO should grow from US$ 128270 million in 2022 to US$ 217220 million by 2029, with a CAGR of 7.7% for the period of 2023-2029.

The key service providers of the Pharmaceutical CDMO in the world are Lonza, Catalent, Thermo Fisher Scientific, Samsung Biologics, Fareva, WuXi AppTech, WuXi Biologics and Siegfried, among which the market share of the top three service providers exceeds 10%, and Lonza is the largest service provider. The services provided by global pharmaceutical CDMO are mainly distributed in North America, Europe and China, among which the top three regions account for nearly 60% of the market share, and North America is currently the largest service provider. In terms of its service type, the growth rate of FDF CDMO is relatively fast. At present, the market share of API CDMO is the highest, more than 40%, followed by FDF CDMO, packaging CDMO and clinical CDMO. In terms of its application, pharmaceutical company are the largest application field, with a market share of more than 60%, followed by biotechnology company.

A CDMO is a company dedicated to providing drug development and manufacturing services for the pharmaceutical and biotechnology industries. CDMO activities can broadly be divided into four fields: product development, manufacture of active pharmaceutical ingredients (API), manufacture of finished dosage forms (FDF) and pharma packaging.

Contract Pharmaceutical Manufacturing is part of CDMO, refers to accept commissioned from pharmaceutical companies, provide the service about API production, FDF production, packaging.

Pharmaceutical companies are likely to outsource a wide range of manufacturing related activities including – primary and secondary packaging, formulation, active ingredient manufacturing, labeling, clinical supplies, sterilization, manufacturing of chemical intermediates, etc. CDMOs support pharmaceutical companies at all stages of the process of making medicines: by providing services in the research and development stages, by offering support in manufacturing, and by providing formulating and finishing processes.

This report aims to provide a comprehensive study of the global market for Pharmaceutical CDMO. Report Highlights:

(1) Global Pharmaceutical CDMO market size (value), history data from 2018-2022 and forecast data from 2023 to 2029.

(2) Global Pharmaceutical CDMO market competitive situation, revenue and market share, from 2018 to 2022.

(3) China Pharmaceutical CDMO market competitive situation, revenue and market share, from 2018 to 2022.

(4) Global Pharmaceutical CDMO segment by region (or country), key regions cover the United States, Europe, Japan, South Korea, Southeast Asia and India, etc.

(5) Global Pharmaceutical CDMO segment by type and by application and regional segment by type and by application.

(6) Pharmaceutical CDMO industry supply chain, upstream, midstream and downstream analysis.

Market segment by regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)

South America (Brazil, Rest of South America)

Middle East & Africa

Market segment by type, covers

API CDMO

FDF CDMO

Packaging CDMO

Clinical CDMO

Market segment by application, can be divided into

Pharmaceutical Company

Biotechnology Company

Other

Market segment by players, this report covers

Lonza

Catalent

Thermo Fisher Scientific

Samsung Biologics

Fareva

WuXi AppTech

WuXi Biologics

Siegfried

FUJIFILM Diosynth Biotechnologies

Asymchem

Pfizer CentreOne

Delpharm

Recipharm

AGC Pharma Chemicals

Boehringer Ingelheim

Vetter

Curia

Aenova

Porton

Piramal

Strides Pharma

NextPharma

Famar

Jubilant

Alcami

Euroapi

Eurofins

Avid Bioservices

BioVectra

CPL

1 Market Overview

1.1 Product Overview and Scope of Pharmaceutical CDMO

1.2 Global Pharmaceutical CDMO Market Size and Forecast

1.3 China Pharmaceutical CDMO Market Size and Forecast

1.4 China Market Percentage in Global

1.4.1 By Revenue, China Pharmaceutical CDMO Share in Global Market, 2018-2029

1.4.2 Pharmaceutical CDMO Market Size: China VS Global, 2018-2029

1.5 Pharmaceutical CDMO Market Dynamics

1.5.1 Pharmaceutical CDMO Market Drivers

1.5.2 Pharmaceutical CDMO Market Restraints

1.5.3 Pharmaceutical CDMO Industry Trends

1.5.4 Pharmaceutical CDMO Industry Policy

2 Global Competitive Situation by Company

2.1 Global Pharmaceutical CDMO Revenue by Company (2018-2023)

2.2 Global Pharmaceutical CDMO Participants, Market Position (Tier 1, Tier 2 and Tier 3)

2.3 Global Pharmaceutical CDMO Concentration Ratio

2.4 Global Pharmaceutical CDMO Mergers & Acquisitions, Expansion Plans

2.5 Global Pharmaceutical CDMO Manufacturers Product Type

3 China Competitive Situation by Company

3.1 China Pharmaceutical CDMO Revenue by Company (2018-2023)

3.2 China Pharmaceutical CDMO Pharmaceutical CDMO Participants, Market Position (Tier 1, Tier 2 and Tier 3)

3.3 China Pharmaceutical CDMO, Revenue Percentage of Local Players VS Foreign Manufacturers (2018-2023)

4 Industry Chain Analysis

4.1 Pharmaceutical CDMO Industry Chain

4.2 Pharmaceutical CDMO Upstream Analysis

4.3 Pharmaceutical CDMO Midstream Analysis

4.4 Pharmaceutical CDMO Downstream Analysis

5 Sights by Type

5.1 Pharmaceutical CDMO Classification

5.1.1 API CDMO

5.1.2 FDF CDMO

5.1.3 Packaging CDMO

5.1.4 Clinical CDMO

5.2 By Type, Global Pharmaceutical CDMO Market Size & CAGR, 2018 VS 2022 VS 2029

5.3 By Type, Global Pharmaceutical CDMO Revenue, 2018-2029

6 Sights by Application

6.1 Pharmaceutical CDMO Segment by Application

6.1.1 Pharmaceutical Company

6.1.2 Biotechnology Company

6.1.3 Other

6.2 By Application, Global Pharmaceutical CDMO Market Size & CAGR, 2018 VS 2022 VS 2029

6.3 By Application, Global Pharmaceutical CDMO Revenue, 2018-2029

7 Sales Sights by Region

7.1 By Region, Global Pharmaceutical CDMO Market Size, 2018 VS 2022 VS 2029

7.2 By Region, Global Pharmaceutical CDMO Market Size, 2018-2029

7.3 North America

7.3.1 North America Pharmaceutical CDMO Market Size & Forecasts, 2018-2029

7.3.2 By Country, North America Pharmaceutical CDMO Market Size Market Share

7.4 Europe

7.4.1 Europe Pharmaceutical CDMO Market Size & Forecasts, 2018-2029

7.4.2 By Country, Europe Pharmaceutical CDMO Market Size Market Share

7.5 Asia Pacific

7.5.1 Asia Pacific Pharmaceutical CDMO Market Size & Forecasts, 2018-2029

7.5.2 By Country/Region, Asia Pacific Pharmaceutical CDMO Market Size Market Share

7.6 South America

7.6.1 South America Pharmaceutical CDMO Market Size & Forecasts, 2018-2029

7.6.2 By Country, South America Pharmaceutical CDMO Market Size Market Share

7.7 Middle East & Africa

8 Sights by Country Level

8.1 By Country, Global Pharmaceutical CDMO Market Size & CAGR，2018 VS 2022 VS 2029

8.2 By Country, Global Pharmaceutical CDMO Market Size, 2018-2029

8.3 U.S.

8.3.1 U.S. Pharmaceutical CDMO Market Size, 2018-2029

8.3.2 By Company, U.S. Pharmaceutical CDMO Revenue Market Share, 2018-2023

8.3.3 By Type, U.S. Pharmaceutical CDMO Revenue Market Share, 2022 VS 2029

8.3.4 By Application, U.S. Pharmaceutical CDMO Revenue Market Share, 2022 VS 2029

8.4 Europe

8.4.1 Europe Pharmaceutical CDMO Market Size, 2018-2029

8.4.2 By Company, Europe Pharmaceutical CDMO Revenue Market Share, 2018-2023

8.4.3 By Type, Europe Pharmaceutical CDMO Revenue Market Share, 2022 VS 2029

8.4.4 By Application, Europe Pharmaceutical CDMO Revenue Market Share, 2022 VS 2029

8.5 China

8.5.1 China Pharmaceutical CDMO Market Size, 2018-2029

8.5.2 By Company, China Pharmaceutical CDMO Revenue Market Share, 2018-2023

8.5.3 By Type, China Pharmaceutical CDMO Revenue Market Share, 2022 VS 2029

8.5.4 By Application, China Pharmaceutical CDMO Revenue Market Share, 2022 VS 2029

8.6 Japan

8.6.1 Japan Pharmaceutical CDMO Market Size, 2018-2029

8.6.2 By Company, Japan Pharmaceutical CDMO Revenue Market Share, 2018-2023

8.6.3 By Type, Japan Pharmaceutical CDMO Revenue Market Share, 2022 VS 2029

8.6.4 By Application, Japan Pharmaceutical CDMO Revenue Market Share, 2022 VS 2029

8.7 South Korea

8.7.1 South Korea Pharmaceutical CDMO Market Size, 2018-2029

8.7.2 By Company, South Korea Pharmaceutical CDMO Revenue Market Share, 2018-2023

8.7.3 By Type, South Korea Pharmaceutical CDMO Revenue Market Share, 2022 VS 2029

8.7.4 By Application, South Korea Pharmaceutical CDMO Revenue Market Share, 2022 VS 2029

8.8 Southeast Asia

8.8.1 Southeast Asia Pharmaceutical CDMO Market Size, 2018-2029

8.8.2 By Company, Southeast Asia Pharmaceutical CDMO Revenue Market Share, 2018-2023

8.8.3 By Type, Southeast Asia Pharmaceutical CDMO Revenue Market Share, 2022 VS 2029

8.8.4 By Application, Southeast Asia Pharmaceutical CDMO Revenue Market Share, 2022 VS 2029

8.9 India

8.9.1 India Pharmaceutical CDMO Market Size, 2018-2029

8.9.2 By Company, India Pharmaceutical CDMO Revenue Market Share, 2018-2023

8.9.3 By Type, India Pharmaceutical CDMO Revenue Market Share, 2022 VS 2029

8.9.4 By Application, India Pharmaceutical CDMO Revenue Market Share, 2022 VS 2029

8.10 Middle East & Asia

8.10.1 Middle East & Asia Pharmaceutical CDMO Market Size, 2018-2029

8.10.2 By Company, Middle East & Asia Pharmaceutical CDMO Revenue Market Share, 2018-2023

8.10.3 By Type, Middle East & Asia Pharmaceutical CDMO Revenue Market Share, 2022 VS 2029

8.10.4 By Application, Middle East & Asia Pharmaceutical CDMO Revenue Market Share, 2022 VS 2029

9 Global Manufacturers Profile

9.1 Lonza

9.1.1 Lonza Company Information, Head Office, Market Area and Industry Position

9.1.2 Lonza Company Profile and Main Business

9.1.3 Lonza Pharmaceutical CDMO Models, Specifications and Application

9.1.4 Lonza Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

9.1.5 Lonza Recent Developments

9.2 Catalent

9.2.1 Catalent Company Information, Head Office, Market Area and Industry Position

9.2.2 Catalent Company Profile and Main Business

9.2.3 Catalent Pharmaceutical CDMO Models, Specifications and Application

9.2.4 Catalent Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

9.2.5 Catalent Recent Developments

9.3 Thermo Fisher Scientific

9.3.1 Thermo Fisher Scientific Company Information, Head Office, Market Area and Industry Position

9.3.2 Thermo Fisher Scientific Company Profile and Main Business

9.3.3 Thermo Fisher Scientific Pharmaceutical CDMO Models, Specifications and Application

9.3.4 Thermo Fisher Scientific Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

9.3.5 Thermo Fisher Scientific Recent Developments

9.4 Samsung Biologics

9.4.1 Samsung Biologics Company Information, Head Office, Market Area and Industry Position

9.4.2 Samsung Biologics Company Profile and Main Business

9.4.3 Samsung Biologics Pharmaceutical CDMO Models, Specifications and Application

9.4.4 Samsung Biologics Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

9.4.5 Samsung Biologics Recent Developments

9.5 Fareva

9.5.1 Fareva Company Information, Head Office, Market Area and Industry Position

9.5.2 Fareva Company Profile and Main Business

9.5.3 Fareva Pharmaceutical CDMO Models, Specifications and Application

9.5.4 Fareva Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

9.5.5 Fareva Recent Developments

9.6 WuXi AppTech

9.6.1 WuXi AppTech Company Information, Head Office, Market Area and Industry Position

9.6.2 WuXi AppTech Company Profile and Main Business

9.6.3 WuXi AppTech Pharmaceutical CDMO Models, Specifications and Application

9.6.4 WuXi AppTech Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

9.6.5 WuXi AppTech Recent Developments

9.7 WuXi Biologics

9.7.1 WuXi Biologics Company Information, Head Office, Market Area and Industry Position

9.7.2 WuXi Biologics Company Profile and Main Business

9.7.3 WuXi Biologics Pharmaceutical CDMO Models, Specifications and Application

9.7.4 WuXi Biologics Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

9.7.5 WuXi Biologics Recent Developments

9.8 Siegfried

9.8.1 Siegfried Company Information, Head Office, Market Area and Industry Position

9.8.2 Siegfried Company Profile and Main Business

9.8.3 Siegfried Pharmaceutical CDMO Models, Specifications and Application

9.8.4 Siegfried Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

9.8.5 Siegfried Recent Developments

9.9 FUJIFILM Diosynth Biotechnologies

9.9.1 FUJIFILM Diosynth Biotechnologies Company Information, Head Office, Market Area and Industry Position

9.9.2 FUJIFILM Diosynth Biotechnologies Company Profile and Main Business

9.9.3 FUJIFILM Diosynth Biotechnologies Pharmaceutical CDMO Models, Specifications and Application

9.9.4 FUJIFILM Diosynth Biotechnologies Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

9.9.5 FUJIFILM Diosynth Biotechnologies Recent Developments

9.10 Asymchem

9.10.1 Asymchem Company Information, Head Office, Market Area and Industry Position

9.10.2 Asymchem Company Profile and Main Business

9.10.3 Asymchem Pharmaceutical CDMO Models, Specifications and Application

9.10.4 Asymchem Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

9.10.5 Asymchem Recent Developments

9.11 Pfizer CentreOne

9.11.1 Pfizer CentreOne Company Information, Head Office, Market Area and Industry Position

9.11.2 Pfizer CentreOne Company Profile and Main Business

9.11.3 Pfizer CentreOne Pharmaceutical CDMO Models, Specifications and Application

9.11.4 Pfizer CentreOne Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

9.11.5 Pfizer CentreOne Recent Developments

9.12 Delpharm

9.12.1 Delpharm Company Information, Head Office, Market Area and Industry Position

9.12.2 Delpharm Company Profile and Main Business

9.12.3 Delpharm Pharmaceutical CDMO Models, Specifications and Application

9.12.4 Delpharm Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

9.12.5 Delpharm Recent Developments

9.13 Recipharm

9.13.1 Recipharm Company Information, Head Office, Market Area and Industry Position

9.13.2 Recipharm Company Profile and Main Business

9.13.3 Recipharm Pharmaceutical CDMO Models, Specifications and Application

9.13.4 Recipharm Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

9.13.5 Recipharm Recent Developments

9.14 AGC Pharma Chemicals

9.14.1 AGC Pharma Chemicals Company Information, Head Office, Market Area and Industry Position

9.14.2 AGC Pharma Chemicals Company Profile and Main Business

9.14.3 AGC Pharma Chemicals Pharmaceutical CDMO Models, Specifications and Application

9.14.4 AGC Pharma Chemicals Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

9.14.5 AGC Pharma Chemicals Recent Developments

9.15 Boehringer Ingelheim

9.15.1 Boehringer Ingelheim Company Information, Head Office, Market Area and Industry Position

9.15.2 Boehringer Ingelheim Company Profile and Main Business

9.15.3 Boehringer Ingelheim Pharmaceutical CDMO Models, Specifications and Application

9.15.4 Boehringer Ingelheim Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

9.15.5 Boehringer Ingelheim Recent Developments

9.16 Vetter

9.16.1 Vetter Company Information, Head Office, Market Area and Industry Position

9.16.2 Vetter Company Profile and Main Business

9.16.3 Vetter Pharmaceutical CDMO Models, Specifications and Application

9.16.4 Vetter Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

9.16.5 Vetter Recent Developments

9.17 Curia

9.17.1 Curia Company Information, Head Office, Market Area and Industry Position

9.17.2 Curia Company Profile and Main Business

9.17.3 Curia Pharmaceutical CDMO Models, Specifications and Application

9.17.4 Curia Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

9.17.5 Curia Recent Developments

9.18 Aenova

9.18.1 Aenova Company Information, Head Office, Market Area and Industry Position

9.18.2 Aenova Company Profile and Main Business

9.18.3 Aenova Pharmaceutical CDMO Models, Specifications and Application

9.18.4 Aenova Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

9.18.5 Aenova Recent Developments

9.19 Porton

9.19.1 Porton Company Information, Head Office, Market Area and Industry Position

9.19.2 Porton Company Profile and Main Business

9.19.3 Porton Pharmaceutical CDMO Models, Specifications and Application

9.19.4 Porton Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

9.19.5 Porton Recent Developments

9.20 Piramal

9.20.1 Piramal Company Information, Head Office, Market Area and Industry Position

9.20.2 Piramal Company Profile and Main Business

9.20.3 Piramal Pharmaceutical CDMO Models, Specifications and Application

9.20.4 Piramal Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

9.20.5 Piramal Recent Developments

9.21 Strides Pharma

9.21.1 Strides Pharma Company Information, Head Office, Market Area and Industry Position

9.21.2 Strides Pharma Company Profile and Main Business

9.21.3 Strides Pharma Pharmaceutical CDMO Models, Specifications and Application

9.21.4 Strides Pharma Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

9.21.5 Strides Pharma Recent Developments

9.22 NextPharma

9.22.1 NextPharma Company Information, Head Office, Market Area and Industry Position

9.22.2 NextPharma Company Profile and Main Business

9.22.3 NextPharma Pharmaceutical CDMO Models, Specifications and Application

9.22.4 NextPharma Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

9.22.5 NextPharma Recent Developments

9.23 Famar

9.23.1 Famar Company Information, Head Office, Market Area and Industry Position

9.23.2 Famar Company Profile and Main Business

9.23.3 Famar Pharmaceutical CDMO Models, Specifications and Application

9.23.4 Famar Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

9.23.5 Famar Recent Developments

9.24 Jubilant

9.24.1 Jubilant Company Information, Head Office, Market Area and Industry Position

9.24.2 Jubilant Company Profile and Main Business

9.24.3 Jubilant Pharmaceutical CDMO Models, Specifications and Application

9.24.4 Jubilant Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

9.24.5 Jubilant Recent Developments

9.25 Alcami

9.25.1 Alcami Company Information, Head Office, Market Area and Industry Position

9.25.2 Alcami Company Profile and Main Business

9.25.3 Alcami Pharmaceutical CDMO Models, Specifications and Application

9.25.4 Alcami Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

9.25.5 Alcami Recent Developments

9.26 Euroapi

9.26.1 Euroapi Company Information, Head Office, Market Area and Industry Position

9.26.2 Euroapi Company Profile and Main Business

9.26.3 Euroapi Pharmaceutical CDMO Models, Specifications and Application

9.26.4 Euroapi Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

9.26.5 Euroapi Recent Developments

9.27 Eurofins

9.27.1 Eurofins Company Information, Head Office, Market Area and Industry Position

9.27.2 Eurofins Company Profile and Main Business

9.27.3 Eurofins Pharmaceutical CDMO Models, Specifications and Application

9.27.4 Eurofins Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

9.27.5 Eurofins Recent Developments

9.28 Avid Bioservices

9.28.1 Avid Bioservices Company Information, Head Office, Market Area and Industry Position

9.28.2 Avid Bioservices Company Profile and Main Business

9.28.3 Avid Bioservices Pharmaceutical CDMO Models, Specifications and Application

9.28.4 Avid Bioservices Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

9.28.5 Avid Bioservices Recent Developments

9.29 BioVectra

9.29.1 BioVectra Company Information, Head Office, Market Area and Industry Position

9.29.2 BioVectra Company Profile and Main Business

9.29.3 BioVectra Pharmaceutical CDMO Models, Specifications and Application

9.29.4 BioVectra Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

9.29.5 BioVectra Recent Developments

9.30 CPL

9.30.1 CPL Company Information, Head Office, Market Area and Industry Position

9.30.2 CPL Company Profile and Main Business

9.30.3 CPL Pharmaceutical CDMO Models, Specifications and Application

9.30.4 CPL Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

9.30.5 CPL Recent Developments

10 Conclusion

11 Appendix

11.1 Research Methodology

11.2 Data Source

11.2.1 Secondary Sources

11.2.2 Primary Sources

11.3 Market Estimation Model

11.4 Disclaimer

Table 1. Pharmaceutical CDMO Market Size & CAGR: China VS Global, (US$ Million), 2018-2029

Table 2. Pharmaceutical CDMO Market Restraints

Table 3. Pharmaceutical CDMO Market Trends

Table 4. Pharmaceutical CDMO Industry Policy

Table 5. Global Pharmaceutical CDMO Revenue by Company (2018-2023) & (US$ million)

Table 6. Global Pharmaceutical CDMO Revenue Market Share by Company (2018-2023)

Table 7. Global Pharmaceutical CDMO Manufacturers Market Concentration Ratio (CR3 and HHI)

Table 8. Global Pharmaceutical CDMO Mergers & Acquisitions, Expansion Plans

Table 9. Global Pharmaceutical CDMO Manufacturers Product Type

Table 10. China Pharmaceutical CDMO Revenue by Company (2018-2023) & (US$ million)

Table 11. China Pharmaceutical CDMO Revenue Market Share by Company (2018-2023)

Table 12. Global Key Players of Pharmaceutical CDMO Upstream (Raw Materials)

Table 13. Global Pharmaceutical CDMO Typical Customers

Table 14. Pharmaceutical CDMO Typical Distributors

Table 15. By Type, Global Pharmaceutical CDMO Revenue & CAGR, 2018 VS 2022 VS 2029, US$ Million

Table 16. By Application, Global Pharmaceutical CDMO Revenue & CAGR, 2018 VS 2022 VS 2029, US$ Million

Table 17. By Region, Global Pharmaceutical CDMO Market Size, 2018 VS 2022 VS 2029, US$ Million

Table 18. By Region, Global Pharmaceutical CDMO Revenue, 2018-2029, US$ Million

Table 19. By Country, Global Pharmaceutical CDMO Revenue & CAGR，2018 VS 2022 VS 2029, US$ Million

Table 20. By Country, Global Pharmaceutical CDMO Revenue, 2018-2029, US$ Million

Table 21. By Country, Global Pharmaceutical CDMO Revenue Market Share, 2018-2029

Table 22. Lonza Company Information, Head Office, Market Area and Industry Position

Table 23. Lonza Company Profile and Main Business

Table 24. Lonza Pharmaceutical CDMO Models, Specifications and Application

Table 25. Lonza Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

Table 26. Lonza Recent Developments

Table 27. Catalent Company Information, Head Office, Market Area and Industry Position

Table 28. Catalent Company Profile and Main Business

Table 29. Catalent Pharmaceutical CDMO Models, Specifications and Application

Table 30. Catalent Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

Table 31. Catalent Recent Developments

Table 32. Thermo Fisher Scientific Company Information, Head Office, Market Area and Industry Position

Table 33. Thermo Fisher Scientific Company Profile and Main Business

Table 34. Thermo Fisher Scientific Pharmaceutical CDMO Models, Specifications and Application

Table 35. Thermo Fisher Scientific Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

Table 36. Thermo Fisher Scientific Recent Developments

Table 37. Samsung Biologics Company Information, Head Office, Market Area and Industry Position

Table 38. Samsung Biologics Company Profile and Main Business

Table 39. Samsung Biologics Pharmaceutical CDMO Models, Specifications and Application

Table 40. Samsung Biologics Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

Table 41. Samsung Biologics Recent Developments

Table 42. Fareva Company Information, Head Office, Market Area and Industry Position

Table 43. Fareva Company Profile and Main Business

Table 44. Fareva Pharmaceutical CDMO Models, Specifications and Application

Table 45. Fareva Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

Table 46. Fareva Recent Developments

Table 47. WuXi AppTech Company Information, Head Office, Market Area and Industry Position

Table 48. WuXi AppTech Company Profile and Main Business

Table 49. WuXi AppTech Pharmaceutical CDMO Models, Specifications and Application

Table 50. WuXi AppTech Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

Table 51. WuXi AppTech Recent Developments

Table 52. WuXi Biologics Company Information, Head Office, Market Area and Industry Position

Table 53. WuXi Biologics Company Profile and Main Business

Table 54. WuXi Biologics Pharmaceutical CDMO Models, Specifications and Application

Table 55. WuXi Biologics Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

Table 56. WuXi Biologics Recent Developments

Table 57. Siegfried Company Information, Head Office, Market Area and Industry Position

Table 58. Siegfried Company Profile and Main Business

Table 59. Siegfried Pharmaceutical CDMO Models, Specifications and Application

Table 60. Siegfried Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

Table 61. Siegfried Recent Developments

Table 62. FUJIFILM Diosynth Biotechnologies Company Information, Head Office, Market Area and Industry Position

Table 63. FUJIFILM Diosynth Biotechnologies Company Profile and Main Business

Table 64. FUJIFILM Diosynth Biotechnologies Pharmaceutical CDMO Models, Specifications and Application

Table 65. FUJIFILM Diosynth Biotechnologies Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

Table 66. FUJIFILM Diosynth Biotechnologies Recent Developments

Table 67. Asymchem Company Information, Head Office, Market Area and Industry Position

Table 68. Asymchem Company Profile and Main Business

Table 69. Asymchem Pharmaceutical CDMO Models, Specifications and Application

Table 70. Asymchem Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

Table 71. Asymchem Recent Developments

Table 72. Pfizer CentreOne Company Information, Head Office, Market Area and Industry Position

Table 73. Pfizer CentreOne Company Profile and Main Business

Table 74. Pfizer CentreOne Pharmaceutical CDMO Models, Specifications and Application

Table 75. Pfizer CentreOne Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

Table 76. Pfizer CentreOne Recent Developments

Table 77. Delpharm Company Information, Head Office, Market Area and Industry Position

Table 78. Delpharm Company Profile and Main Business

Table 79. Delpharm Pharmaceutical CDMO Models, Specifications and Application

Table 80. Delpharm Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

Table 81. Delpharm Recent Developments

Table 82. Recipharm Company Information, Head Office, Market Area and Industry Position

Table 83. Recipharm Company Profile and Main Business

Table 84. Recipharm Pharmaceutical CDMO Models, Specifications and Application

Table 85. Recipharm Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

Table 86. Recipharm Recent Developments

Table 87. AGC Pharma Chemicals Company Information, Head Office, Market Area and Industry Position

Table 88. AGC Pharma Chemicals Company Profile and Main Business

Table 89. AGC Pharma Chemicals Pharmaceutical CDMO Models, Specifications and Application

Table 90. AGC Pharma Chemicals Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

Table 91. AGC Pharma Chemicals Recent Developments

Table 92. Boehringer Ingelheim Company Information, Head Office, Market Area and Industry Position

Table 93. Boehringer Ingelheim Company Profile and Main Business

Table 94. Boehringer Ingelheim Pharmaceutical CDMO Models, Specifications and Application

Table 95. Boehringer Ingelheim Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

Table 96. Boehringer Ingelheim Recent Developments

Table 97. Vetter Company Information, Head Office, Market Area and Industry Position

Table 98. Vetter Company Profile and Main Business

Table 99. Vetter Pharmaceutical CDMO Models, Specifications and Application

Table 100. Vetter Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

Table 101. Vetter Recent Developments

Table 102. Curia Company Information, Head Office, Market Area and Industry Position

Table 103. Curia Company Profile and Main Business

Table 104. Curia Pharmaceutical CDMO Models, Specifications and Application

Table 105. Curia Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

Table 106. Curia Recent Developments

Table 107. Aenova Company Information, Head Office, Market Area and Industry Position

Table 108. Aenova Company Profile and Main Business

Table 109. Aenova Pharmaceutical CDMO Models, Specifications and Application

Table 110. Aenova Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

Table 111. Aenova Recent Developments

Table 112. Porton Company Information, Head Office, Market Area and Industry Position

Table 113. Porton Company Profile and Main Business

Table 114. Porton Pharmaceutical CDMO Models, Specifications and Application

Table 115. Porton Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

Table 116. Porton Recent Developments

Table 117. Piramal Company Information, Head Office, Market Area and Industry Position

Table 118. Piramal Company Profile and Main Business

Table 119. Piramal Pharmaceutical CDMO Models, Specifications and Application

Table 120. Piramal Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

Table 121. Piramal Recent Developments

Table 122. Strides Pharma Company Information, Head Office, Market Area and Industry Position

Table 123. Strides Pharma Company Profile and Main Business

Table 124. Strides Pharma Pharmaceutical CDMO Models, Specifications and Application

Table 125. Strides Pharma Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

Table 126. Strides Pharma Recent Developments

Table 127. NextPharma Company Information, Head Office, Market Area and Industry Position

Table 128. NextPharma Company Profile and Main Business

Table 129. NextPharma Pharmaceutical CDMO Models, Specifications and Application

Table 130. NextPharma Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

Table 131. NextPharma Recent Developments

Table 132. Famar Company Information, Head Office, Market Area and Industry Position

Table 133. Famar Company Profile and Main Business

Table 134. Famar Pharmaceutical CDMO Models, Specifications and Application

Table 135. Famar Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

Table 136. Famar Recent Developments

Table 137. Jubilant Company Information, Head Office, Market Area and Industry Position

Table 138. Jubilant Company Profile and Main Business

Table 139. Jubilant Pharmaceutical CDMO Models, Specifications and Application

Table 140. Jubilant Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

Table 141. Jubilant Recent Developments

Table 142. Alcami Company Information, Head Office, Market Area and Industry Position

Table 143. Alcami Company Profile and Main Business

Table 144. Alcami Pharmaceutical CDMO Models, Specifications and Application

Table 145. Alcami Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

Table 146. Alcami Recent Developments

Table 147. Euroapi Company Information, Head Office, Market Area and Industry Position

Table 148. Euroapi Company Profile and Main Business

Table 149. Euroapi Pharmaceutical CDMO Models, Specifications and Application

Table 150. Euroapi Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

Table 151. Euroapi Recent Developments

Table 152. Eurofins Company Information, Head Office, Market Area and Industry Position

Table 153. Eurofins Company Profile and Main Business

Table 154. Eurofins Pharmaceutical CDMO Models, Specifications and Application

Table 155. Eurofins Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

Table 156. Eurofins Recent Developments

Table 157. Avid Bioservices Company Information, Head Office, Market Area and Industry Position

Table 158. Avid Bioservices Company Profile and Main Business

Table 159. Avid Bioservices Pharmaceutical CDMO Models, Specifications and Application

Table 160. Avid Bioservices Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

Table 161. Avid Bioservices Recent Developments

Table 162. BioVectra Company Information, Head Office, Market Area and Industry Position

Table 163. BioVectra Company Profile and Main Business

Table 164. BioVectra Pharmaceutical CDMO Models, Specifications and Application

Table 165. BioVectra Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

Table 166. BioVectra Recent Developments

Table 167. CPL Company Information, Head Office, Market Area and Industry Position

Table 168. CPL Company Profile and Main Business

Table 169. CPL Pharmaceutical CDMO Models, Specifications and Application

Table 170. CPL Pharmaceutical CDMO Revenue and Gross Margin, 2018-2023

Table 171. CPL Recent Developments

List of Figure

Figure 1. Pharmaceutical CDMO Picture

Figure 2. Global Pharmaceutical CDMO Industry Market Size and Forecast (US$ million) & (2018-2029)

Figure 3. China Pharmaceutical CDMO Revenue and Forecast (US$ million) & (2018-2029)

Figure 4. 2018-2029 China Pharmaceutical CDMO Market Share of Global

Figure 5. Global Pharmaceutical CDMO Key Participants, Market Share, 2021 VS 2022 VS 2023

Figure 6. Global Pharmaceutical CDMO Market Share by Company, (Tier 1, Tier 2 and Tier 3), 2018-2023

Figure 7. China Pharmaceutical CDMO Key Participants, Market Share, 2021 VS 2022 VS 2023

Figure 8. China Pharmaceutical CDMO Revenue, Domestic VS Import Products, Proportion of China Local Players and Foreign Players, 2018-2023

Figure 9. Pharmaceutical CDMO Industry Chain

Figure 10. API CDMO

Figure 11. FDF CDMO

Figure 12. Packaging CDMO

Figure 13. Clinical CDMO

Figure 14. By Type, Global Pharmaceutical CDMO Revenue, 2018-2029, US$ Million

Figure 15. By Type, Global Pharmaceutical CDMO Revenue Market Share, 2018-2029

Figure 16. Pharmaceutical Company

Figure 17. Biotechnology Company

Figure 18. Other

Figure 19. By Application, Global Pharmaceutical CDMO Revenue, 2018-2029, US$ Million

Figure 20. By Application, Global Pharmaceutical CDMO Revenue Market Share, 2018-2029

Figure 21. By Region, Global Pharmaceutical CDMO Revenue Market Share, 2018-2029

Figure 22. North America Pharmaceutical CDMO Revenue & Forecasts, 2018-2029, US$ Million

Figure 23. By Country, North America Pharmaceutical CDMO Revenue Market Share, 2018-2023

Figure 24. Europe Pharmaceutical CDMO Revenue & Forecasts, 2018-2029, US$ Million

Figure 25. By Country, Europe Pharmaceutical CDMO Revenue Market Share, 2018-2023

Figure 26. Asia Pacific Pharmaceutical CDMO Revenue & Forecasts, 2018-2029, US$ Million

Figure 27. By Country/Region, Asia Pacific Pharmaceutical CDMO Revenue Market Share, 2018-2023

Figure 28. South America Pharmaceutical CDMO Revenue & Forecasts, 2018-2029, US$ Million

Figure 29. By Country, South America Pharmaceutical CDMO Revenue Market Share, 2018-2023

Figure 30. Middle East & Africa Pharmaceutical CDMO Revenue & Forecasts, 2018-2029, US$ Million

Figure 31. U.S. Pharmaceutical CDMO Revenue, 2018-2029, (US$ Million)

Figure 32. By Company, U.S. Pharmaceutical CDMO Market Share, 2018-2023

Figure 33. By Type, U.S. Pharmaceutical CDMO Revenue Market Share, 2022 VS 2029

Figure 34. By Application, U.S. Pharmaceutical CDMO Revenue Market Share, 2022 VS 2029

Figure 35. Europe Pharmaceutical CDMO Revenue, 2018-2029, (US$ Million)

Figure 36. By Company, Europe Pharmaceutical CDMO Market Share, 2018-2023

Figure 37. By Type, Europe Pharmaceutical CDMO Revenue Market Share, 2022 VS 2029

Figure 38. By Application, Europe Pharmaceutical CDMO Revenue Market Share, 2022 VS 2029

Figure 39. China Pharmaceutical CDMO Revenue, 2018-2029, (US$ Million)

Figure 40. By Company, China Pharmaceutical CDMO Market Share, 2018-2023

Figure 41. By Type, China Pharmaceutical CDMO Revenue Market Share, 2022 VS 2029

Figure 42. By Application, China Pharmaceutical CDMO Revenue Market Share, 2022 VS 2029

Figure 43. Japan Pharmaceutical CDMO Revenue, 2018-2029, (US$ Million)

Figure 44. By Company, Japan Pharmaceutical CDMO Market Share, 2018-2023

Figure 45. By Type, Japan Pharmaceutical CDMO Revenue Market Share, 2022 VS 2029

Figure 46. By Application, Japan Pharmaceutical CDMO Revenue Market Share, 2022 VS 2029

Figure 47. South Korea Pharmaceutical CDMO Revenue, 2018-2029, (US$ Million)

Figure 48. By Company, South Korea Pharmaceutical CDMO Market Share, 2018-2023

Figure 49. By Type, South Korea Pharmaceutical CDMO Revenue Market Share, 2022 VS 2029

Figure 50. By Application, South Korea Pharmaceutical CDMO Revenue Market Share, 2022 VS 2029

Figure 51. Southeast Asia Pharmaceutical CDMO Revenue, 2018-2029, (US$ Million)

Figure 52. By Company, Southeast Asia Pharmaceutical CDMO Market Share, 2018-2023

Figure 53. By Type, Southeast Asia Pharmaceutical CDMO Revenue Market Share, 2022 VS 2029

Figure 54. By Application, Southeast Asia Pharmaceutical CDMO Revenue Market Share, 2022 VS 2029

Figure 55. India Pharmaceutical CDMO Revenue, 2018-2029, (US$ Million)

Figure 56. By Company, India Pharmaceutical CDMO Market Share, 2018-2023

Figure 57. By Type, India Pharmaceutical CDMO Revenue Market Share, 2022 VS 2029

Figure 58. By Application, India Pharmaceutical CDMO Revenue Market Share, 2022 VS 2029

Figure 59. Middle East & Asia Pharmaceutical CDMO Revenue, 2018-2029, (US$ Million)

Figure 60. By Company, Middle East & Asia Pharmaceutical CDMO Market Share, 2018-2023

Figure 61. By Type, Middle East & Asia Pharmaceutical CDMO Revenue Market Share, 2022 VS 2029

Figure 62. By Application, Middle East & Asia Pharmaceutical CDMO Revenue Market Share, 2022 VS 2029

Figure 63. Research Methodology

Figure 64. Breakdown of Primary Interviews

Figure 65. Bottom-up Approaches

Figure 66. Top-down Approaches

Methodology/Research Approach

This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.

Research Programs/Design

Historical Data (2015-2019)	Industry Trends Competitive Landscape By Company Expansion Mergers and Acquisitions Market Segment by Type by Application By Regions/ Geography	Value Status and Outlook Value for Major Players Market Share Growth Rate Present Situation Analysis Value Market Share Growth Rate Present Situation Analysis
Influencing Factors	Market Environment Government Policy Technological Changes Market Risks	Market Drivers Growing Demand of Downstream Reduction in Cost
Market Forecast (2021-2026)	Overall Size by Type by Application By Regions/Geography	Key Data (Value) Market Share Growth Rate CAGR (2021-2026)

Market Size Estimation

Top-down and bottom-up approaches are used to validate the global Voluntary Carbon Offset market size market and estimate the market size for Company, regions segments, product segments and Application (end users).

The market estimations in this report are based on the marketed sale price of Voluntary Carbon Offset (excluding any discounts provided by the player, distributor, wholesaler or traders). The percentage splits, market share, and breakdowns of the product segments are derived on the basis of weights assigned to each of the segments on the basis of their utilization rate and average sale price. The regional splits of the overall Voluntary Carbon Offset market and its sub-segments are based on the percentage adoption or utilization of the given product in the respective region or country.

Major Company in the market is identified through secondary research and their market revenues determined through primary and secondary research. Secondary research included the research of the annual and financial reports of the top Company; whereas, primary research included extensive interviews of key opinion leaders and industry experts such as experienced front-line staff, directors, CEOs and marketing executives. The percentage splits, market share, Growth Rate and breakdowns of the product markets are determined through using secondary sources and verified through the primary sources.

All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or other factors are not accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Market Intellix and presented in this report

The following figure shows an illustrative representation of the overall market size estimation process used for this study.

Market Breakdown and Data Triangulation

After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation, extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.

Data Source

Secondary Sources

Secondary sources include such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, etc. This research study involves the usage of widespread secondary sources, directories, databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), and TRADING ECONOMICS, and News Network, statista, Federal Reserve Economic Data, annual reports, BIS Statistics, ICIS; company house documents; CAS(American Chemical Society); investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and Hospitals study of the Voluntary Carbon Offset market. It was also used to obtain important information about the top companies, market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives.

Market Size	Segmental value Geographic Penetration Product Adoption Rate for Different market	Journals, Websites, and Press Releases Annual Reports and SEC Filings Company Websites and Press Releases Public and Paid Databases Market Intellix Data Repository
Market Position of Top Company	Product Financials Geographic value Mix Total Company value Business/Segmental value Mix
Qualitative Analysis	Influence Factors Market Potential Market Risks and Opportunities Industry Trends Geographical Features Government Policies	Company Websites and Press Releases Public and Paid Databases Annual Reports Industry Associations Market Intellix Data Repository

Primary Sources

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product Company (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.

The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end use (product buyers), and related key executives from various key companies and organizations operating in the global market.

Primary research was conducted to identify segmentation Type, product price range, product Application, key Company, raw materials supply and the downstream demand, industry status and outlook, and key market dynamics such as risks, influence factors, opportunities, market barriers, industry trends, and key player strategies.

Key Executives Interviewed

Key Data Information from Primary Sources

Primary Sources	Parameters	Key Data
Market Segments(by Application, by Type)	Value by Type Status and Forecast Value by Application Value by Regions, Status and Forecast (2021-2026)	Value Market Share by Type Value Growth Rate by Type Value by Application Percentage and Growth Rate by Application Value Growth Rate and Market Share by Regions Market Size Status and Forecast (2021-2026)
Total Market	Overall Size, Status and Forecast	Market Size Status and Forecast (2021-2026)